Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 11:02 a.m.

    📋 ABCELLERA BIOLOGICS INC. (ABCL) - Clinical Trial Update

    Filing Date: 2022-06-30

    Accepted: 2022-06-30 13:28:17

    Event Type: Clinical Trial Update

    Event Details:

    Abcellera Biologics Inc (ABCL) Announces Clinical Trial Update Abcellera Biologics Inc (ABCL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: authorized, resulting
    • Diseases/Conditions: an additional 350, COVID-19
    • Collaboration: COVID-19

    🔬 Clinical Development Pipeline (ABCELLERA BIOLOGICS INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo BIOLOGICAL Phase PHASE1 Vasomotor Symptoms Associated With Menopause ClinicalTrials.gov
    ABCL635 BIOLOGICAL Phase PHASE1 Vasomotor Symptoms Associated With Menopause ClinicalTrials.gov
    QBKPN SSI BIOLOGICAL Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov
    QBECO DRUG Phase PHASE1 Crohn's Disease ClinicalTrials.gov
    Placebo (Normal Saline 0.9%) BIOLOGICAL Phase EARLY_PHASE1 Healthy Volunteers ClinicalTrials.gov
    ABCL575 BIOLOGICAL Phase EARLY_PHASE1 Healthy Volunteers ClinicalTrials.gov
    Lenalidomide DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Romidepsin DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Abcellera Biologics Inc
    • CIK: 0001703057
    • Ticker Symbol: ABCL
    • Period End Date: 2022-06-29
    • Document Type: 8-K

Search

News categories